Cat. No. 4779
Chemical Name: 2-[[3-(1,3-dioxo-1H-benz[de]isoquin
Biological ActivitySelective lysophosphatidic acid 2 (LPA2) receptor non-lipid agonist (EC50 = 3.3 μM). Does not activate other LPA GPCRs at concentrations up to 10 μM. Antiapoptotic; inhibits activation of caspases 3, 7, 8 and 9, Bax translocation and PARP-1 cleavage. Activates ERK1/2 survival pathway.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Kiss et al (2013) Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim.Biophys.Acta 1831 117. PMID: 23127512.
Kiss et al (2012) Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol.Pharmacol. 82 1162. PMID: 22968304.
If you know of a relevant reference for GRI 977143 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GRI 977143 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GRI 977143, supplier, GRI977143, lysophospholipid, acid, 2, LPA2, inhibitors, inhibits, antiapoptotic, caspases, Bax, PARP-1, cleavage, ERK1/2, ERK, survival, pathway, apoptosis, Tocris Bioscience, Lysophosphatidic Acid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Highly potent GPR183 (EBI2) agonistAR-C 69931 tetrasodium salt
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppressantCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonist
July 8 - 12, 2017